Render Target: STATIC
Render Timestamp: 2024-09-26T10:57:15.198Z
Commit: 60a5021c3a47fc24d1656fb463e2c3c41a1ad145
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

PADI2 (E3P8Z) Rabbit mAb #97647

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 76
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    PADI2 (E3P8Z) Rabbit mAb recognizes endogenous levels of total PADI2 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Gly375 of human PADI2 protein.

    Background

    Peptidyl arginine deiminase (PAD) proteins are a family of Ca2+-dependent enzymes that catalyze the post-translational conversion of arginine to citrulline. There are currently five known PAD isozymes in humans, referred to as PADI1-4 and PADI6 (1). Among these isozymes, peptidyl arginine deiminase type 2 (PADI2) is the most widely expressed, being found in skeletal muscle, brain, colon, breast, macrophages, spleen, and spinal cord tissue, among others (1,2). In normal mouse development, PADI2 expression levels are elevated from 18 days to 2 months of age, and gradually decrease from 3 months onward (3). Some of the most well studied PADI2 substrates include vimentin, actin, myelin basic protein (MBP), glial fibrillary acidic protein (GFAP), and histones (4). PADI2-mediated citrullination has been shown to be involved in neurodegeneration and inflammatory response-associated diseases such as multiple sclerosis (MS), Alzheimer’s disease (AD), psoriasis, and rheumatoid arthritis (5). Excessive PAD-mediated deimination of MBP is believed to be a major contributor to MS disease progression, while elevated levels of citrullinated GFAP and vimentin proteins have been found in the brains of AD patients (2,4). PADI2 has also been found to play a role in the progression of several types of cancers, including colorectal, breast, and prostate (5-7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    XP is a registered trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.